Straits Times Index
3,199.01 +25.19 (+0.79%) S&P 500
4,507.24 +20.78 (+0.46%) Dow
35,379.00 +120.39 (+0.34%) Nasdaq
15,080.71 +58.91 (+0.39%) BTC-USD
62,604.86 +800.20 (+1.29%) CMC Crypto 200
1,459.04 -4.32 (-0.30%)
Takeda Pharmaceutical Company Limited (TAK)
| Previous close | 13.96 |
| Open | 13.93 |
| Bid | 14.00 x 3000 |
| Ask | 14.01 x 800 |
| Day's range | 13.93 - 14.03 |
| 52-week range | 13.91 - 19.97 |
| Volume | 253,512 |
| Avg. volume | 2,167,944 |
| Market cap | 44.423B |
| Beta (5Y monthly) | 1.10 |
| PE ratio (TTM) | 11.71 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.84 (5.94%) |
| Ex-dividend date | 30 Mar 2021 |
| 1y target est | N/A |
- Business Wire
BioLife Plasma Services Announces Expansion of Plasma Donation Centers into Massachusetts
WORCESTER, Mass., October 13, 2021--BioLife Plasma Services announces new center opening in Worcester, MA to support an urgent need for plasma donations.
- Business Wire
FDA Advisory Committee Recommends Use of Investigational Drug Maribavir (TAK-620) to Treat Post-Transplant Recipients with Cytomegalovirus (CMV) Infection and Disease Refractory to Treatment With or Without Resistance
OSAKA, Japan & CAMBRIDGE, Mass., October 07, 2021--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced the U.S. Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously to recommend use of maribavir (TAK-620) for the treatment of refractory cytomegalovirus (CMV) infection and disease with genotypic resistance to ganciclovir, valganciclovir, foscarnet or cidofovir in transplant recipients. The committee also voted unanimo
- Business Wire
Takeda Provides Update on TAK-994 Clinical Program
OSAKA, Japan & CAMBRIDGE, Mass., October 05, 2021--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that a safety signal has emerged in Phase 2 studies of TAK-994, an investigational oral orexin agonist. As an immediate precautionary measure, the company has suspended dosing of patients and has decided to stop both Phase 2 studies early. This allows for the timely interpretation of the benefit /risk profile of TAK-994 and to determine next steps for the progra
